 Home > Active Ingredient News > Blood System > Eur J Cancer: Efficacy and safety of Sepalizumab (GLS-010) in the treatment of Chinese patients with relapsed or refractory classic Hodgkin's lymphoma

Eur J Cancer: Efficacy and safety of Sepalizumab (GLS-010) in the treatment of Chinese patients with relapsed or refractory classic Hodgkin's lymphoma

 Last Update: 2021-09-11
 Source: Internet
 Author: User

Tags

2 4 concentrate

all colors

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Hodgkin's lymphoma (HL) is a rare hematological malignancy that originates in the lymphatic system
.
GLS-010 (Zimberelimab, Sepalimumab) is a new, fully human, anti-programmed death-1 monoclonal antibody that has shown good efficacy and safety in advanced solid tumors

Lymphoma GLS-010 (Zimberelimab, Sepalimumab) is a new, fully human, anti-programmed death-1 monoclonal antibody GLS-010 (Zimberelimab, Sepalimumab) is a new type , Fully human, anti-programmed death-1 monoclonal antibody

This study aims to evaluate the efficacy and safety of GLS-010 in Chinese patients with relapsed/refractory classic Hodgkin lymphoma (r/r-cHL)
.

This is a single-arm, open-label Phase 2 trial conducted in 24 medical centers in China, recruiting patients with r/r-cHL who have undergone second- or more-line treatment
.
GLS-010 (240 mg, once every 2 weeks) was given to the test patients until the disease progressed, death, intolerable toxicity, or withdrawal from the test

Progression-free survival

Between August 2018 and August 2019, a total of 85 patients were recruited
.
The median follow-up was 15.

8 months

Seventy-seven (90.

Adverse events with an incidence> 10%

Treatment-related adverse events (TRAE) were observed in 92.
9% of subjects
.
Twenty-four (28.

2%) of 85 patients had grade 3/4 TRAE

Treatment-related adverse events (TRAE) were observed in 92.

GLS-010 (Zimberelimab) has therapeutic activity in Chinese r/r-cHL patients with controllable safety GLS-010 (Zimberelimab) has therapeutic activity in Chinese r/r-cHL patients with controllable safety

Original source:

Lin Ningjing,Zhang Mingzhi,Bai Hai et al.

Efficacy and safety of GLS-010 ( zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.